Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates (Q38067436)

28 August 2017

1 reference

title

Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates (English)

1 reference

28 August 2017

1 reference

4

C Blake Gilks

1 reference

28 August 2017

Ananta Gurung

1

1 reference

28 August 2017

Tawny Hung

series ordinal

2

1 reference

28 August 2017

Jason Morin

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

62

1 reference

28 August 2017

59-70

1 reference

28 August 2017

1

1 reference

Diverse tumorigenic pathways in ovarian serous carcinoma

28 August 2017

1 reference

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

21 January 2018

1 reference

Critical molecular abnormalities in high-grade serous carcinoma of the ovary

21 January 2018

1 reference

The fallopian tube: primary site of most pelvic high-grade serous carcinomas.

21 January 2018

1 reference

21 January 2018

Carcinoma of the ovary

1 reference

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

21 January 2018

1 reference

High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression.

21 January 2018

1 reference

Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

21 January 2018

1 reference

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

21 January 2018

1 reference

The impact of p53 and p73 on aneuploidy and cancer

21 January 2018

1 reference

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

21 January 2018

1 reference

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 January 2018

1 reference

Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment

21 January 2018

1 reference

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

21 January 2018

1 reference

STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis

21 January 2018

1 reference

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

21 January 2018

1 reference

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

21 January 2018

1 reference

Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase

21 January 2018

1 reference

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

21 January 2018

1 reference

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction

21 January 2018

1 reference

Ovarian carcinoma pathology and genetics: recent advances

21 January 2018

1 reference

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

21 January 2018

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer

21 January 2018

1 reference

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

21 January 2018

1 reference

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

21 January 2018

1 reference

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

21 January 2018

1 reference

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

21 January 2018

1 reference

Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial

21 January 2018

1 reference

Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases

21 January 2018

1 reference

ARID1A mutations in endometriosis-associated ovarian carcinomas

21 January 2018

1 reference

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

21 January 2018

1 reference

PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.

21 January 2018

1 reference

PP2A: the expected tumor suppressor

21 January 2018

1 reference

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas

21 January 2018

1 reference

Somatic mutations of PPP2R1A in ovarian and uterine carcinomas

21 January 2018

1 reference

Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma

21 January 2018

1 reference

A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary

21 January 2018

1 reference

Identification of novel therapeutic targets in microdissected clear cell ovarian cancers

21 January 2018

1 reference

Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.

21 January 2018

1 reference

Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors.

21 January 2018

1 reference

Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation

21 January 2018

1 reference

Endometriosis and the development of malignant tumours of the pelvis. A review of literature

21 January 2018

1 reference

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer

21 January 2018

1 reference

Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers

21 January 2018

1 reference

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

21 January 2018

1 reference

Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.

21 January 2018

1 reference

Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data

21 January 2018

1 reference

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm

21 January 2018

1 reference

Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.

21 January 2018

1 reference

Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature

21 January 2018

1 reference

Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

21 January 2018

1 reference

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

21 January 2018

1 reference

Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.

21 January 2018

1 reference

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

21 January 2018

1 reference

Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

21 January 2018

1 reference

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.

21 January 2018

1 reference

The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway

21 January 2018

1 reference

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma

21 January 2018

1 reference

Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.

21 January 2018

1 reference

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

21 January 2018

1 reference

Low-grade serous carcinomas of the ovary contain very few point mutations

21 January 2018

1 reference

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

21 January 2018

1 reference

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary

21 January 2018

1 reference

Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas

21 January 2018

1 reference

The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis

21 January 2018

1 reference

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

21 January 2018

1 reference

Targeting the extracellular signal-regulated kinase pathway in cancer therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HIS.12033

1 reference

28 August 2017

1 reference